Systematic review of dasatinib in chronic myeloid leukemia

References

• KeamSJDasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemiaBio Drugs20082215969
   Google Scholar
• JabbourECortesJKantarjianHDasatinib for the treatment of Philadelphia chromosome-positive leukemiasExpert Opin Investig Drugs2007165679687
   PubMed Web of Science ®Google Scholar
• MullerMCCortesJEKimDWDasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutationsBlood2009114244944495319779040
   PubMed Web of Science ®Google Scholar
• ShahNPDasatinibDrugs Today (Barc)200743151217315048
   PubMed Web of Science ®Google Scholar
• NamSWilliamsAVulturADasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cellsMol Cancer Ther2007641400140517431118
   PubMed Web of Science ®Google Scholar
• SteinbergMDasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemiaClin Ther200729112289230818158072
   PubMed Web of Science ®Google Scholar
• MinematsuTGiacominiKMInteractions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsMol Cancer Ther201110353153921252289
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantar jianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med2006354242531254116775234
   PubMed Web of Science ®Google Scholar
• CortesJSawyersCLKantarjianHLong-term efficacy of dasatinib in chronic phase CML: results from the phase I trial (CA180002)Blood20071101026
   Web of Science ®Google Scholar
• HochhausAKantarjianHBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapyBlood200711052303230917138817
   PubMed Web of Science ®Google Scholar
• BranfordSHochhausAMuellerMAnalysis of molecular data and the emergence of mutations for chronic-phase chronic myelogenous leukemia (CML-CP) patients treated with dasatinib after imatinib failureBlood20091143282
   Web of Science ®Google Scholar
• HochhausABaccaraniMDeinigerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia20082261200120618401416
   PubMed Web of Science ®Google Scholar
• KantarjianHPasquiniRLevyVDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Cancer2009115183935394319517473
   PubMed Web of Science ®Google Scholar
• ApperleyJFCortesJEKimDWDasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START trialJ Clin Oncol200927213472347919487385
   PubMed Web of Science ®Google Scholar
• CortesJRousselotPKimDWDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisisBlood200710983207321317185463
   PubMed Web of Science ®Google Scholar
• OttmannODombretHMartinelliGDasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyBlood200711072309231517496201
   PubMed Web of Science ®Google Scholar
• ShahNPKimDWKantarjianHPotent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibHaematologica201095223224020139391
   PubMed Web of Science ®Google Scholar
• ReaDVellengaEJunghanCSix-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia (CML-CP) receiving dasatinibHaematologica201297Suppl 1199
   Google Scholar
• PemmarajuNKantarjianHLuthraRResults of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phaseBlood20111181700
   Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• GilesFMahonFXGjertsenBDevelopmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukemiaEur J Clin Invest20124291016102622548456
   PubMed Web of Science ®Google Scholar
• Pinilla-IbarzJFlinnIThe expanding options for front-line treatment in patients with newly diagnosed CMLCrit Rev Oncol Hematol201284228729922487423
   PubMed Web of Science ®Google Scholar
• ThieneltCDGreenKBowlesDWNew and established tyrosine kinase inhibitors for chronic myeloid leukemiaDrugs Today (Barc)201248960161323032801
   PubMed Web of Science ®Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood201211951123112922160483
   PubMed Web of Science ®Google Scholar
• BrecciaMEfficaceFAlimenaGProgressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who’s afraid of the big bad wolf?Leuk Res201236781381422483067
   PubMed Web of Science ®Google Scholar
• MontaniDBergotEGuntherSPulmonary arterial hypertension in patients treated by dasatinibCirculation2012125172128213722451584
   PubMed Web of Science ®Google Scholar
• HochhausABoqueCGarelikBMolecular response kinetics and bcr-abl reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-years follow-upHaematologica201297Suppl 1192
   Google Scholar
• RadichJPKopeckyKJAppelbaumFRA randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaBlood2012120193898390522915637
   PubMed Web of Science ®Google Scholar
• RavandiFO’BrienSThomasDFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaBlood2010116122070207720466853
   PubMed Web of Science ®Google Scholar
• FoaRVitaleAVignettiMDasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaBlood2011118256521652821931113
   PubMed Web of Science ®Google Scholar
• CoplandMHamiltonAElrickLJDasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood2006107114532453916469872
   PubMed Web of Science ®Google Scholar
• KonigHCoplandMChuSEffects of dasatinib on SRC kinase activity and downstream intracellular signalling in primitive chronic myelogenous leukemia hematopoietic cellsCancer Res200868239624963319047139
   PubMed Web of Science ®Google Scholar
• CoplandMPellicanoFRichmondLBMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitorsBlood2008111852843285318156496
   PubMed Web of Science ®Google Scholar
• BellodiCLidonniciMRHamiltonATargeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cellsJ Clin Invest200911951109112319363292
   PubMed Web of Science ®Google Scholar
• GoffDJRecartACSadaranganiAA pan BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibitionCell Stem Cell1152013 [Epub ahead of print.]
   Google Scholar